Tamoxifen Citrate is a selective estrogen receptor modulator (SERM) with one of the most extensively documented clinical histories of any pharmaceutical compound. FDA approved since 1977 and remaining among the most studied SERMs across oncology and endocrinology research literature. This formulation delivers 20mg per tablet in a 100 count format, double the tablet supply of CSD’s F40 Biotech Nolvadex 20mg 50 tablet listing at identical compound and concentration, providing extended research supply continuity suited to longer duration protocols or laboratories maintaining standing Tamoxifen inventory across ongoing HPG axis and estrogen modulation research programs.
The 100 tablet format serves a distinct procurement purpose from the 50 tablet presentation. For research protocols examining Tamoxifen’s HPG axis restoration activity across extended observation windows where the compound’s CYP2D6 dependent Endoxifen conversion and tissue selective estrogen receptor modulation are being evaluated across multiple weeks. The 100 tablet supply eliminates mid protocol restocking and ensures consistent compound source quality across the full research timeline from a single procurement. For laboratories running multiple simultaneous Tamoxifen research protocols across different experimental groups, the higher tablet count provides a practical bulk sourcing option without committing to separate procurement events for each protocol cycle.
Tamoxifen’s core pharmacological profile remains consistent with CSD’s F40 Biotech 50 tablet listing, tissue selective SERM activity producing estrogen receptor antagonism at the hypothalamic pituitary axis and breast tissue while exerting partial agonist effects at bone and liver, CYP2D6 prodrug activation to the high affinity metabolite Endoxifen, and well documented HPG axis stimulation through hypothalamic estrogen receptor blockade driving increased LH and FSH secretion. The 100 tablet format and generic brand sourcing represent the primary differentiating variables from the F40 Biotech presentation; base compound, concentration, and pharmacological activity remaining identical across both listings.
Every batch of CSD’s Tamoxifen is third party lab tested for concentration accuracy and purity before being made available, with COA documentation available on request. Canada Steroid Depot has supplied Canadian customers with consistently verified, accurately dosed research compounds for years, and our SERM range across Tamoxifen, Clomiphene, and Enclomiphene represents comprehensive estrogen receptor modulation research coverage from a single verified Canadian supplier. All orders ship discreetly across Canada in plain, unmarked packaging with no identifying information on the exterior.
Store in a cool, dry place away from direct light and heat. Intended for research purposes only.
Commonly researched alongside Clomiphene and HCG in comparative SERM and HPG axis restoration studies. Browse CSD’s full PCT range for complete sourcing.
